Cadrenal Therapeutics (CVKD) Non-Current Debt (2022)
Cadrenal Therapeutics (CVKD) posted Non-Current Debt of $250000.0 for Q4 2022.
Cadrenal Therapeutics (CVKD) Non-Current Debt (2022) Analysis & Trends
Cadrenal Therapeutics has reported Non-Current Debt for 1 years, with the latest figure at $250000.0 in Q4 2022.
- Quarterly Non-Current Debt changed N/A year-over-year to $250000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $250000.0 (changed N/A YoY) and the FY2022 annual result came in at $250000.0, changed N/A from the prior year.
- Non-Current Debt was little changed at $250000.0 in Q4 2022 per CVKD's latest filing.
- Over five years, Non-Current Debt peaked at $250000.0 in Q4 2022 and troughed at $250000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 8.96 Bn |
| 10 | Cadrenal Therapeutics | 4.66 Mn | 2.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 250,000.00 |